Literature DB >> 9369936

Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast.

T Hasebe1, S Imoto, T Ogura, K Mukai.   

Abstract

A fibrotic focus (FF) is a scar-like area within invasive ductal carcinoma (IDC) of the breast, and has been shown to be a marker of high aggressiveness of IDC. In order to investigate the mechanism of FF formation in IDC, expression of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor (FGFR) was studied. One hundred and forty-nine IDCs were divided into solid tumors and scirrhous tumors. Immunohistochemistry was used to determine the expression of bFGF and FGFR proteins in both tumor cells and fibroblasts forming FF. Scirrhous tumors with FF showed a significantly higher frequency of bFGF protein expression than those without (P = 0.017), whereas, in solid tumors, the presence of FF was not significantly associated with the frequency of bFGF protein expression (P = 0.143). In addition, scirrhous tumors showed a significantly higher frequency of FGFR protein expression than solid tumors (P = 0.001). Among IDCs having FF and expressing bFGF protein, a significantly larger number of fibroblasts expressing FGFR protein within FF was observed in scirrhous tumors than in solid tumors (P = 0.016). The results of this study suggest that in scirrhous tumors the interaction between tumor cells and stromal fibroblasts plays an important role in the formation of FF, and that there is a paracrine mechanism between bFGF protein from tumor cells and FGFR protein in fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369936      PMCID: PMC5921517          DOI: 10.1111/j.1349-7006.1997.tb00464.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  20 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury.

Authors:  C Henke; W Marineili; J Jessurun; J Fox; D Harms; M Peterson; L Chiang; P Doran
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

3.  Growth control of A431 cells in protein-free medium: secretory products do not affect cell growth.

Authors:  Y Masuda; Y Yoshitake; K Nishikawa
Journal:  In Vitro Cell Dev Biol       Date:  1988-09

4.  Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair.

Authors:  G F Pierce; J E Tarpley; D Yanagihara; T A Mustoe; G M Fox; A Thomason
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

5.  Expression of the FGFR1 gene in human breast-carcinoma cells.

Authors:  J Jacquemier; J Adelaide; P Parc; F Penault-Llorca; J Planche; O deLapeyriere; D Birnbaum
Journal:  Int J Cancer       Date:  1994-11-01       Impact factor: 7.396

6.  Immunohistochemical localization of growth factors in fetal wound healing.

Authors:  D J Whitby; M W Ferguson
Journal:  Dev Biol       Date:  1991-09       Impact factor: 3.582

7.  Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance.

Authors:  C Yiangou; J J Gomm; R C Coope; M Law; Y A Luqmani; S Shousha; R C Coombes; C L Johnston
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  Recent developments in the cell biology of basic fibroblast growth factor.

Authors:  D B Rifkin; D Moscatelli
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

9.  Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues.

Authors:  Y A Luqmani; M Graham; R C Coombes
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

10.  Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness.

Authors:  T Hasebe; H Tsuda; S Hirohashi; Y Shimosato; M Iwai; S Imoto; K Mukai
Journal:  Jpn J Cancer Res       Date:  1996-04
View more
  6 in total

1.  Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1.

Authors:  M V Cronauer; S Stadlmann; H Klocker; B Abendstein; I E Eder; H Rogatsch; A G Zeimet; C Marth; F A Offner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  A visual-quantitative analysis of fibroblastic stromagenesis in breast cancer progression.

Authors:  Edna Cukierman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

3.  Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections.

Authors:  Sasisekhar Bennuru; Grace Maldarelli; V Kumaraswami; Amy D Klion; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  Histological factors associated with initial bone metastasis of invasive ductal carcinoma of the breast.

Authors:  T Koyama; T Hasebe; H Tsuda; S Hirohashi; S Sasaki; T Fukutomi; S Imoto; T Umeda; K Mukai
Journal:  Jpn J Cancer Res       Date:  1999-03

5.  A proposal for a new histological classification scheme for predicting short-term tumor recurrence and death in patients with invasive ductal carcinoma of the breast.

Authors:  T Hasebe; S Imoto; S Sasaki; K Mukai
Journal:  Jpn J Cancer Res       Date:  1998-12

6.  Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4.

Authors:  Ubaldo E Martinez-Outschoorn; Joseph M Curry; Ying-Hui Ko; Zhao Lin; Madalina Tuluc; David Cognetti; Ruth C Birbe; Edmund Pribitkin; Alessandro Bombonati; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2013-07-08       Impact factor: 4.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.